Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorANDRADE, Diocesio Alves Pinto de-
dc.contributor.authorSILVA, Luciane Sussuchi da-
dc.contributor.authorLAUS, Ana Carolina-
dc.contributor.authorLIMA, Marcos Alves de-
dc.contributor.authorBERARDINELLI, Gustavo Noriz-
dc.contributor.authorSILVA, Vinicius Duval da-
dc.contributor.authorMATSUSHITA, Graziela de Macedo-
dc.contributor.authorBONATELLI, Murilo-
dc.contributor.authorSILVA, Aline Larissa Virginio da-
dc.contributor.authorEVANGELISTA, Adriane Feijo-
dc.contributor.authorCARVALHO, Jesus Paula-
dc.contributor.authorREIS, Rui Manuel-
dc.contributor.authorREIS, Ricardo dos-
dc.identifier.citationFRONTIERS IN ONCOLOGY, v.11, 2021-
dc.description.abstractBackground The molecular profile of endometrial cancer has become an important tool in determining patient prognosis and their optimal adjuvant treatment. In addition to The Cancer Genome Atlas (TCGA), simpler tools have been developed, such as the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE). We attempted to determine a genetic signature to build a recurrence risk score in patients diagnosed with low- and intermediate-risk endometrial cancer. Methods A case-control study was conducted. The eligible patients were women diagnosed with recurrence low- and intermediate-risk endometrial cancer between January 2009 and December 2014 at a single institution; the recurrence patients were matched to two nonrecurrence patients with the same diagnosis by age and surgical staging. Following RNA isolation of 51 cases, 17 recurrence and 34 nonrecurrence patients, the expression profile was determined using the nCounter(R) PanCancer Pathways Panel, which contains 770 genes. Results The expression profile was successfully characterized in 49/51 (96.1%) cases. We identified 12 genes differentially expressed between the recurrence and nonrecurrence groups. The ROC curve for each gene was generated, and all had AUCs higher than 0.7. After backward stepwise logistic regression, four genes were highlighted: FN1, DUSP4, LEF1, and SMAD9. The recurrence risk score was calculated, leading to a ROC curve of the 4-gene model with an AUC of 0.93, sensitivity of 100%, and specificity of 72.7%. Conclusion We identified a four-gene signature that may be associated with recurrence in patients with low- and intermediate-risk endometrial cancer. This finding suggests a new prognostic factor in this poorly explored group of patients with endometrial cancer.eng
dc.description.sponsorshipBarretos Cancer Hospital-
dc.description.sponsorshipPublic Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer Project), Campinas, Brazil-
dc.description.sponsorshipCNPq productivity fellowshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)-
dc.publisherFRONTIERS MEDIA SAeng
dc.relation.ispartofFrontiers in Oncology-
dc.subjectlow- and intermediate-risk endometrioid endometrial carcinomaeng
dc.subjectgenetic signatureeng
dc.subjectrecurrence risk scoreeng
dc.subject.otherclinical consequenceseng
dc.titleA 4-Gene Signature Associated With Recurrence in Low- and Intermediate-Risk Endometrial Cancereng
dc.rights.holderCopyright FRONTIERS MEDIA SAeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Diocesio Alves Pinto de:Oncol Inst Ribeirao Preto, InORP ONCOCLIN Grp, Ribeirao Preto, Brazil; Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil-, Luciane Sussuchi da:Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil-, Ana Carolina:Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil-, Marcos Alves de:Barretos Canc Hosp, Epidemiol & Biostat Nucleus, Barretos, Brazil-, Gustavo Noriz:Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil-, Vinicius Duval da:Barretos Canc Hosp, Dept Pathol, Barretos, Brazil-, Graziela de Macedo:Barretos Canc Hosp, Dept Pathol, Barretos, Brazil-, Murilo:Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil-, Aline Larissa Virginio da:Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil-, Adriane Feijo:Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil-, Rui Manuel:Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil; Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Portugal-, Ricardo dos:Barretos Canc Hosp, Dept Gynecol Oncol, Barretos, Brazil-
hcfmusp.relation.referenceAndre F, 2021, ANN ONCOL, V32, P208, DOI 10.1016/j.annonc.2020.11.011eng
hcfmusp.relation.reference[Anonymous], 2020, ESTIMATIVA 2020 INCIeng
hcfmusp.relation.referenceBendifallah S, 2014, BRIT J CANCER, V110, P2640, DOI 10.1038/bjc.2014.237eng
hcfmusp.relation.referenceBerardinelli Gustavo Noriz, 2018, Oncotarget, V9, P28691, DOI 10.18632/oncotarget.25611eng
hcfmusp.relation.referenceBerg HF, 2020, BRIT J CANCER, V122, P1014, DOI 10.1038/s41416-020-0745-6eng
hcfmusp.relation.referenceBOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7eng
hcfmusp.relation.referenceBritton H, 2019, GYNECOL ONCOL, V153, P487, DOI 10.1016/j.ygyno.2019.03.098eng
hcfmusp.relation.referenceCampanella NC., 2020, PATHOBIOLOGY, V87, P208, DOI [10.1159/000507373, DOI 10.1159/000507373]eng
hcfmusp.relation.referenceChen BN, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.554214eng
hcfmusp.relation.referenceDai ZT, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022861eng
hcfmusp.relation.referencede Boer SM, 2018, ANN ONCOL, V29, P424, DOI 10.1093/annonc/mdx753eng
hcfmusp.relation.referenceDeng F, 2021, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.587822eng
hcfmusp.relation.referenceGao LM, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02654-9eng
hcfmusp.relation.referenceGetz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113eng
hcfmusp.relation.referenceGomes I, 2021, J NEURO-ONCOL, V151, P135, DOI 10.1007/s11060-020-03675-6eng
hcfmusp.relation.referenceGu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313eng
hcfmusp.relation.referenceHarris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010eng
hcfmusp.relation.referenceHoreweg N, 2020, CANCER IMMUNOL RES, V8, P1508, DOI 10.1158/2326-6066.CIR-20-0149eng
hcfmusp.relation.referenceHsu YT, 2016, CANCER RES, V76, P6171, DOI 10.1158/0008-5472.CAN-16-0752eng
hcfmusp.relation.referenceKaspers M, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.02.041eng
hcfmusp.relation.referenceKurnit KC, 2017, MODERN PATHOL, V30, P1032, DOI 10.1038/modpathol.2017.15eng
hcfmusp.relation.referenceLeal LF, 2018, NEUROPATHOLOGY, V38, P475, DOI 10.1111/neup.12508eng
hcfmusp.relation.referenceManion E, 2008, AM J SURG PATHOL, V32, P732, DOI 10.1097/PAS.0b013e31815a04f5eng
hcfmusp.relation.referenceMcMellen A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124272eng
hcfmusp.relation.referenceMisirlioglu S, 2012, EUR J GYNAECOL ONCOL, V33, P610eng
hcfmusp.relation.referenceMoroney MR, 2019, GYNECOL ONCOL, V153, P517, DOI 10.1016/j.ygyno.2019.03.100eng
hcfmusp.relation.referenceNgeow J, 2015, GASTROENTEROLOGY, V149, P886, DOI 10.1053/j.gastro.2015.06.027eng
hcfmusp.relation.referencede Andrade DAP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220086eng
hcfmusp.relation.referenceR Core Team, 2019, R LANG ENV STAT COMPeng
hcfmusp.relation.referenceRaglan O, 2020, TRANSL RES, V218, P57, DOI 10.1016/j.trsl.2019.12.003eng
hcfmusp.relation.referenceRobin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77eng
hcfmusp.relation.referenceRosa MN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38315-7eng
hcfmusp.relation.referenceShelton DN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040312eng
hcfmusp.relation.referenceSiegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654eng
hcfmusp.relation.referenceSmrz SA, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.10.042eng
hcfmusp.relation.referenceStelloo E, 2016, CLIN CANCER RES, V22, P4215, DOI 10.1158/1078-0432.CCR-15-2878eng
hcfmusp.relation.referenceSzklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131eng
hcfmusp.relation.referenceTalhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190eng
hcfmusp.relation.referenceWaggott D, 2012, BIOINFORMATICS, V28, P1546, DOI 10.1093/bioinformatics/bts188eng
hcfmusp.relation.referenceWang ZW, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5717498eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MOG
Departamento de Obstetrícia e Ginecologia - FM/MOG

Artigos e Materiais de Revistas Científicas - LIM/58
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
art_ANDRADE_A_4Gene_Signature_Associated_With_Recurrence_in_Low_2021.PDFpublishedVersion (English)1.13 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.